Pharmaceutical giants tracking Mylan's prosperity
Analysts say that CEO Robert J. Coury's efforts to shove Mylan Inc. onto the world pharmaceutical stage could lead to one conclusion -- a Mylan takeover.
"Mylan undoubtedly is being looked at," said Ken Cacciatore, who follows Cecil, Washington County-based Mylan for Cowen & Co. in New York. "In a consolidating industry, with international opportunities being looked at more and more, Mylan definitely is in an advantageous position. If a large pharmaceutical company is looking to diversify, Mylan is an obvious choice."
"Mylan is certainly on the radar screen of Pfizer and Novartis," said David Moskowitz, a Washington, D.C.-based analyst who follows Mylan for Caris & Co., New York.
Mylan might garner some $6.8 billion in a buyout, according to Motley Fool contributor Brian Orelli, after subtracting corporate debt of $4.7 billion.
New York-based Pfizer is the world's second-largest pharmaceutical company and Basel, Switzerland-based Novartis is the fifth-largest.
Last year, Mylan spent $740 million to acquire a majority share in the world's second-largest generic drug ingredient maker, India's Matrix, then overruled conventional wisdom of some industry watchers by spending $6.8 billion -- 70 percent more than Mylan's value at the time -- to acquire the generics business of Germany's Merck KGaA.
Within months, Mylan jumped from third-largest generic drugmaker in the United States to third-largest generic company in the world with 13,000 employees and a product portfolio of 570 market products, doing business in more than 90 countries.
Cacciatore said it's much easier to buy a distribution network like Mylan's rather than try over time to build one. "You have scale built-in and already in place," he said.
The only part of Mylan that hasn't grown in the last year has been the company's stock price, which is mired in the $13 range. Its highest stock price in the last year was $16.87, reached on Oct. 3, the day after the Merck deal closed. Mylan's market capitalization today is about $4.3 billion. Its stock closed Tuesday at $13.66, down 32 cents.
Cacciatore in a recent research note projected that Mylan's revenues will jump 110.4 percent in four years, to $5.6 billion in 2011, from $2.7 billion last year. Operating profits, excluding all merger-related charges, in the same timeframe will more than double, to $651.4 million from last year's $325.5 million.
"Coury's delivering on promises on the way to digesting two acquisitions last year," analyst Moskowitz said.
Coury said on the day after the Merck generics deal closed in October that one of his next goals was to have a women's health care portfolio, including products such as hormone replacement and birth control drugs.
Last week, Mylan announced it had signed a deal with India-based Famy Care Ltd. to develop and supply 22 oral contraceptive medicines to U.S. customers. "Through our partnership with Famy Care, we have met another long-standing commitment by expanding our portfolio to create a women's health care franchise," Coury said. He could not be reached for comment yesterday.
"Entering the oral contraceptives field, that currently is a duopoly controlled by Barr Pharmaceuticals and Watson Pharmaceuticals, makes Mylan more attractive," Moskowitz said.
Barr is one of the most recent acquisitions in the pharmaceutical business. Earlier this year, the world's No. 1 generic drug company, Israel-based Teva Pharmaceutical Industries Ltd., announced it would pay $7.5 billion plus assume $1.5 billion in debt for No. 4 Barr.
Another recent merger brought together Japan's third-largest branded drugmaker, Daiichi Sankyo, with India's largest generic drugmaker, Ranbaxy Laboratories, in a $4.6 billion deal.
"It's not clear if any of the large pharmaceutical companies will get involved in buying generic companies," Cacciatore said. "Novartis with Sandoz already is one of the top three generic companies."
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Intruder in Carrick makes off with cash, weapon
- Steelers veteran linebacker Harrison focused on stretch run
- Crosby scores twice, Malkin delivers OT goal as Penguins beat Blues
- Friends, family, history lure natives back to Western Pennsylvania
- Penguins co-owner Lemieux snuffs rumored rift with Crosby
- Emotional send-off awaits Pitt seniors
- Steelers notebook: Tomlin ends practice with third-down work
- Starkey: Artie Rowell’s incredible odyssey
- Annual Holiday Parade to celebrate all things Pittsburgh
- 1 dead, 1 injured after crash in North Point Breeze
- Artis leads Pitt to lopsided victory over Cornell